Mark C Gillies. Show Affiliations »
Abstract
Entities: Chemical
Mesh： See more » Angiogenesis Inhibitors/economicsAngiogenesis Inhibitors/therapeutic useAnimalsAnterior Eye Segment/blood supplyAntibodies, Monoclonal/economicsAntibodies, Monoclonal/therapeutic useAntibodies, Monoclonal, HumanizedBevacizumabCornea/blood supplyCost-Benefit AnalysisEye/blood supplyHumansMacular Degeneration/drug therapyNeovascularization, Pathologic/drug therapyOphthalmology/methodsRanibizumabVascular Endothelial Growth Factor A/antagonists & inhibitors
Substances： See more » Angiogenesis InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedVascular Endothelial Growth Factor ABevacizumabRanibizumab
Year: 2010 PMID： 20642588 DOI： 10.1111/j.1442-9071.2010.02300.x
Source DB: PubMed Journal: Clin Exp Ophthalmol ISSN： 1442-6404 Impact factor: 4.207